Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Market Cap & Net Worth: Carmat (ALCAR)
Carmat (PA:ALCAR) has a market capitalization of $6.53 Million (€6.36 Million) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #32709 globally and #373 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Carmat's stock price €0.10 by its total outstanding shares 64254002 (64.25 Million).
Carmat Market Cap History: 2015 to 2026
Carmat's market capitalization history from 2015 to 2026. Data shows change from $2.62 Billion to $6.53 Million (-45.35% CAGR).
Index Memberships
Carmat is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$8.71 Billion | 0.04% | #15 of 34 |
Weight: Carmat's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Carmat Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Carmat's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.27x
Carmat's market cap is 10.27 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.62 Billion | $14.35K | -$17.55 Million | 182284.36x | N/A |
| 2016 | $1.83 Billion | $173.17K | -$22.98 Million | 10577.58x | N/A |
| 2017 | $1.38 Billion | $28.00K | -$29.23 Million | 49353.63x | N/A |
| 2018 | $1.50 Billion | $14.00K | -$41.73 Million | 107092.02x | N/A |
| 2019 | $1.23 Billion | $14.00K | -$42.65 Million | 87860.97x | N/A |
| 2020 | $1.81 Billion | $9.00K | -$36.96 Million | 200614.49x | N/A |
| 2021 | $1.30 Billion | $2.23 Million | -$61.87 Million | 582.47x | N/A |
| 2022 | $665.43 Million | $345.00K | -$53.68 Million | 1928.79x | N/A |
| 2023 | $427.45 Million | $2.85 Million | -$53.87 Million | 150.09x | N/A |
| 2024 | $71.89 Million | $7.00 Million | -$51.40 Million | 10.27x | N/A |
Competitor Companies of ALCAR by Market Capitalization
Companies near Carmat in the global market cap rankings as of March 18, 2026.
Key companies related to Carmat by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
Carmat Historical Marketcap From 2015 to 2026
Between 2015 and today, Carmat's market cap moved from $2.62 Billion to $ 6.53 Million, with a yearly change of -45.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.53 Million | 0.00% |
| 2025 | €6.53 Million | -90.92% |
| 2024 | €71.89 Million | -83.18% |
| 2023 | €427.45 Million | -35.76% |
| 2022 | €665.43 Million | -48.75% |
| 2021 | €1.30 Billion | -28.09% |
| 2020 | €1.81 Billion | +46.78% |
| 2019 | €1.23 Billion | -17.96% |
| 2018 | €1.50 Billion | +8.49% |
| 2017 | €1.38 Billion | -24.56% |
| 2016 | €1.83 Billion | -29.98% |
| 2015 | €2.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Carmat was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.53 Million USD |
| MoneyControl | $6.53 Million USD |
| MarketWatch | $6.53 Million USD |
| marketcap.company | $6.53 Million USD |
| Reuters | $6.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.